This prospective blood-based biomarker study, START-TKI, in EGFR-mutated NSCLC patients reports poor predictive markers based on cfDNA and TKI drug concentrations during EGFR-TKI treatment which have potential to be used in clinical practice in the future. Here, EGFR is linked to non-small cell lung carcinoma.